Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02472457 · ClinicalTrials.gov registry record · NA
Crohn Disease Exclusion Diet After Single Medication De-escalation
A NA study, sponsored by Children's Hospital of Philadelphia.
- Completed
- Registry status
- NA
- Development phase
- 19
- Enrollment target
NCT02472457: Completed NA study, sponsored by Children's Hospital of Philadelphia.
NCT02472457 is a NA study that has completed, run by Children's Hospital of Philadelphia. The registered enrollment target is 19 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02472457, a NA study, has completed, sponsored by Children's Hospital of Philadelphia.
- COMPLETED
- Registry status
- NA
- Development phase
- 19 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine whether pediatric Crohn Disease (CD) patients in long-standing remission remain in remission longer after stopping medications if they follow the Crohn's Disease Exclusion Diet (CDED). The hypothesis is that subjects on the CDED will have longer time-to-relapse as opposed to those on an unrestricted diet.
Primary Outcome
Remission defined by the Pediatric Crohn Disease Activity Index, C-reactive protein, and stool calprotectin
Interventions
- OTHER Crohn Disease Exclusion Diet
- OTHER Free Diet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2015-08 |
| Est. Completion | 2020-09 |
| Phase | NA |
What the finished NCT02472457 record still lists
NCT02472457 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Crohn Disease Exclusion Diet is the first listed.
NCT02472457 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02472457 about?
NCT02472457 is a clinical study titled "Crohn Disease Exclusion Diet After Single Medication De-escalation". The primary objective of this study is to determine whether pediatric Crohn Disease (CD) patients in long-standing remission remain in remission longer after stopping medications if they follow the Crohn's Disease Exclusion Diet (CDED). The hypothesis is that subjects on the CDED will have longer ti...
What is the current status of trial NCT02472457?
This trial is currently completed. It is a NA study. The enrollment target is 19 participants. The study started on 2015-08. Estimated completion is 2020-09.
What interventions are being tested in trial NCT02472457?
The interventions under investigation include: Crohn Disease Exclusion Diet (OTHER), Free Diet (OTHER).
Who is sponsoring clinical trial NCT02472457?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02472457's enrollment target sits among peer trials
19 1861st of 2000 higher than 138 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia